![Graziano Seghezzi](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Graziano Seghezzi
Director/Board Member at Corvidia Therapeutics, Inc.
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Jean-Jacques Garaud | M | 69 |
Inotrem SA
![]() Inotrem SA BiotechnologyHealth Technology Inotrem SA specializes in the development of therapeutic approaches based on its proprietary TREM-1 platform. The firm focuses on the control of immune reactions in acute inflammatory diseases. The company was founded by Jean-Jacques Garaud, Marc Derive and Sebastien Gibot in 2013 and is headquartered in Paris, France. | 11 years |
Gilles Nobécourt | M | 67 |
GlycoVaxyn AG
![]() GlycoVaxyn AG BiotechnologyHealth Technology GlycoVaxyn AG developed and produced bioconjugate vaccines. The company was founded in 2004 and was headquartered in Schlieren, Switzerland.
Inotrem SA
![]() Inotrem SA BiotechnologyHealth Technology Inotrem SA specializes in the development of therapeutic approaches based on its proprietary TREM-1 platform. The firm focuses on the control of immune reactions in acute inflammatory diseases. The company was founded by Jean-Jacques Garaud, Marc Derive and Sebastien Gibot in 2013 and is headquartered in Paris, France.
Crescendo Biologics Ltd.
![]() Crescendo Biologics Ltd. Miscellaneous Commercial ServicesCommercial Services Crescendo Biologics Ltd. engages in the development of new medicines based on antibody fragment technology. Its products in pipeline in dermatology include CB001, a transformational Humabody-based topical biologic for psoriasis which combines exceptional activity against a validated target with a topical route of delivery to avoid systemic side effects. The firm?s oncology products in pipeline include Humabody Multi-Specific T-Cell Engagers, Humabody Antibody Drug Conjugates and Immune Checkpoint Inhibitors. The company was founded by Michael Anthony Romanos, David Rayll Brown and John Bradshaw on November 13, 2007 and is headquartered in Cambridge, the United Kingdom. | - |
Jörn Aldag | M | 65 |
GeneSpire Srl
![]() GeneSpire Srl BiotechnologyHealth Technology GeneSpire Srl is a holding company, which engages in the development of transformative gene therapies for patients with genetic diseases. The company was founded by Luigi Naldini and Alessio Cantone in March 2020 and is headquartered in Milan, Italy.
Hookipa Biotech AG
![]() Hookipa Biotech AG Medical SpecialtiesHealth Technology Hookipa Biotech AG develops new generation prophylactic and therapeutic vaccines. The firm’s Vaxwave technology is a novel immunotherapy platform using a replication-defective viral vector for the prevention and treatment of cancer and infectious diseases. The company was founded by Lukas Flatz, Andreas Bergthaler, Rolf M. Zinkernagel and Daniel Pinschewer in July 2011 and is headquartered in Vienna, Austria. | 8 years |
Michael Krel | M | - |
Sofinnova Partners SAS
![]() Sofinnova Partners SAS Investment ManagersFinance Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco. | 11 years |
Dominique Sirena | M | - |
GlycoEra AG
![]() GlycoEra AG BiotechnologyHealth Technology GlycoEra AG is a Swiss biotechnology company specializing in the development of novel biologics for various indications. The company is based in Schlieren, Switzerland, and the USA. The company utilizes its innovative customglycan platform to design, engineer, and develop medicines based on deep expertise in glycobiology. GlycoEra has raised over $49 million in a 2021 series A financing round co-led by 5AM Ventures, Sofinnova Partners, and Roche Venture Fund. The company was founded by Dominique Sirena, Amir Faridmoayer, and Veronica Gambillara Fonck. Ganesh Venkataraman Kaundinya has been the CEO of the company since 2020. | - |
Alex Leech | M | - |
Creabilis Holdings Ltd.
![]() Creabilis Holdings Ltd. Pharmaceuticals: MajorHealth Technology Creabilis Holdings Ltd. operates as a biotechnology company. The company was founded on June 7, 2013 and is headquartered in Canterbury, the United Kingdom.
Sofinnova Partners SAS
![]() Sofinnova Partners SAS Investment ManagersFinance Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco. | 3 years |
Jonathan Montagu | M | - |
HotSpot Therapeutics, Inc.
![]() HotSpot Therapeutics, Inc. BiotechnologyHealth Technology HotSpot Therapeutics, Inc. develops new allosteric therapies with the ability to treat disease. The company was founded by Jonathan Montagu and Geraldine Harriman and is headquartered in Boston, MA. | - |
Philippe Dro | M | 61 |
GlycoVaxyn AG
![]() GlycoVaxyn AG BiotechnologyHealth Technology GlycoVaxyn AG developed and produced bioconjugate vaccines. The company was founded in 2004 and was headquartered in Schlieren, Switzerland.
GlycoEra AG
![]() GlycoEra AG BiotechnologyHealth Technology GlycoEra AG is a Swiss biotechnology company specializing in the development of novel biologics for various indications. The company is based in Schlieren, Switzerland, and the USA. The company utilizes its innovative customglycan platform to design, engineer, and develop medicines based on deep expertise in glycobiology. GlycoEra has raised over $49 million in a 2021 series A financing round co-led by 5AM Ventures, Sofinnova Partners, and Roche Venture Fund. The company was founded by Dominique Sirena, Amir Faridmoayer, and Veronica Gambillara Fonck. Ganesh Venkataraman Kaundinya has been the CEO of the company since 2020. | 2 years |
Sander J. van Deventer | M | 69 |
Hookipa Biotech AG
![]() Hookipa Biotech AG Medical SpecialtiesHealth Technology Hookipa Biotech AG develops new generation prophylactic and therapeutic vaccines. The firm’s Vaxwave technology is a novel immunotherapy platform using a replication-defective viral vector for the prevention and treatment of cancer and infectious diseases. The company was founded by Lukas Flatz, Andreas Bergthaler, Rolf M. Zinkernagel and Daniel Pinschewer in July 2011 and is headquartered in Vienna, Austria. | 10 years |
Jean-Guillaume Lafay | M | - |
Mablink Bioscience
![]() Mablink Bioscience Pharmaceuticals: MajorHealth Technology Mablink Bioscience is a biotechnology company based in Lyon, France that develops next-generation antibody-drug conjugates for the treatment of solid tumors. Mablink Bioscience's exclusive PSarlink™ platform is a unique stealth technology that "masks" the hydrophobicity of the cytotoxic drugs by adding a polysarcosine chain to the linker. The French company's pipeline is built on the topoisomerase-I inhibitor exatecan as a payload for current developments. Recently, the company announced the publication of a review article titled “Payload Diversification\: A Key Step in the Development of Antibody–Drug Conjugates” which reviews the history of the successes and failures in ADC payloads and takes a look at the new roads currently explored by the industry. The company was founded in 2018 by Warren Viricel and Jean-Guillaume Lafay, with Jean-Guillaume Lafay serving as CEO since then. | - |
Daniel D. Pinschewer | M | 49 |
Hookipa Biotech AG
![]() Hookipa Biotech AG Medical SpecialtiesHealth Technology Hookipa Biotech AG develops new generation prophylactic and therapeutic vaccines. The firm’s Vaxwave technology is a novel immunotherapy platform using a replication-defective viral vector for the prevention and treatment of cancer and infectious diseases. The company was founded by Lukas Flatz, Andreas Bergthaler, Rolf M. Zinkernagel and Daniel Pinschewer in July 2011 and is headquartered in Vienna, Austria. | 13 years |
Antoine Papiernik | M | 57 |
Sofinnova Partners SAS
![]() Sofinnova Partners SAS Investment ManagersFinance Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco. | 27 years |
Mauro Magnani | M | 71 |
EryDel SpA
![]() EryDel SpA Medical SpecialtiesHealth Technology EryDel SpA offers medical research. It develops drugs and diagnostics delivered through human red blood cells via a medical device technology. The company was founded by Luigia Rossi and Mauro Magnani in 2007 and is headquartered in Bresso, Italy. | 17 years |
Amir Faridmoayer | M | - |
GlycoEra AG
![]() GlycoEra AG BiotechnologyHealth Technology GlycoEra AG is a Swiss biotechnology company specializing in the development of novel biologics for various indications. The company is based in Schlieren, Switzerland, and the USA. The company utilizes its innovative customglycan platform to design, engineer, and develop medicines based on deep expertise in glycobiology. GlycoEra has raised over $49 million in a 2021 series A financing round co-led by 5AM Ventures, Sofinnova Partners, and Roche Venture Fund. The company was founded by Dominique Sirena, Amir Faridmoayer, and Veronica Gambillara Fonck. Ganesh Venkataraman Kaundinya has been the CEO of the company since 2020. | - |
Thierry Hercend | M | - |
Inotrem SA
![]() Inotrem SA BiotechnologyHealth Technology Inotrem SA specializes in the development of therapeutic approaches based on its proprietary TREM-1 platform. The firm focuses on the control of immune reactions in acute inflammatory diseases. The company was founded by Jean-Jacques Garaud, Marc Derive and Sebastien Gibot in 2013 and is headquartered in Paris, France. | - |
Ganesh Venkataraman Kaundinya | M | 57 |
GlycoEra AG
![]() GlycoEra AG BiotechnologyHealth Technology GlycoEra AG is a Swiss biotechnology company specializing in the development of novel biologics for various indications. The company is based in Schlieren, Switzerland, and the USA. The company utilizes its innovative customglycan platform to design, engineer, and develop medicines based on deep expertise in glycobiology. GlycoEra has raised over $49 million in a 2021 series A financing round co-led by 5AM Ventures, Sofinnova Partners, and Roche Venture Fund. The company was founded by Dominique Sirena, Amir Faridmoayer, and Veronica Gambillara Fonck. Ganesh Venkataraman Kaundinya has been the CEO of the company since 2020. | 4 years |
Ruben Herrendorff | M | - |
Polyneuron Pharmaceuticals AG
![]() Polyneuron Pharmaceuticals AG Pharmaceuticals: MajorHealth Technology Polyneuron Pharmaceuticals AG develops drugs for the treatment of autoimmune disorders. It develops drugs for the treatment of anti-MAG neuropathy disease and multifocal motor neuropathy disease. The firm also develops antibody-catch, a platform technology that enables the development of drugs for highly specific interception of autoimmune disease antibodies and focuses on autoimmune diseases of the peripheral nervous system that involve autoantibodies against carbohydrate epitopes. The company was founded by Andreas J. Steck, Beat Ernst, Pascal Hänggi and Ruben Herrendorffin in 2014 and is headquartered in Basel, Switzerland. | 10 years |
Marc Derive | M | - |
Inotrem SA
![]() Inotrem SA BiotechnologyHealth Technology Inotrem SA specializes in the development of therapeutic approaches based on its proprietary TREM-1 platform. The firm focuses on the control of immune reactions in acute inflammatory diseases. The company was founded by Jean-Jacques Garaud, Marc Derive and Sebastien Gibot in 2013 and is headquartered in Paris, France. | 11 years |
Michael Kelly | M | 67 |
Hookipa Biotech AG
![]() Hookipa Biotech AG Medical SpecialtiesHealth Technology Hookipa Biotech AG develops new generation prophylactic and therapeutic vaccines. The firm’s Vaxwave technology is a novel immunotherapy platform using a replication-defective viral vector for the prevention and treatment of cancer and infectious diseases. The company was founded by Lukas Flatz, Andreas Bergthaler, Rolf M. Zinkernagel and Daniel Pinschewer in July 2011 and is headquartered in Vienna, Austria. | 5 years |
Jan van de Winkel | M | 63 |
Hookipa Biotech AG
![]() Hookipa Biotech AG Medical SpecialtiesHealth Technology Hookipa Biotech AG develops new generation prophylactic and therapeutic vaccines. The firm’s Vaxwave technology is a novel immunotherapy platform using a replication-defective viral vector for the prevention and treatment of cancer and infectious diseases. The company was founded by Lukas Flatz, Andreas Bergthaler, Rolf M. Zinkernagel and Daniel Pinschewer in July 2011 and is headquartered in Vienna, Austria. | 7 years |
Jens Stegemann | M | - |
Breath Therapeutics GmbH
![]() Breath Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Breath Therapeutics GmbH is a clinical stage biopharmaceutical company, which engages in the development of inhaled therapeutics for respiratory diseases. It offers drug device platform, which consists of liposomal drug-aerosol formulations and cutting-edge inhalation technology. The company was founded by Jens Stegemann, Gerhard Boerner, Oliver Denk, and Anne Burger in 2016 and is headquartered in Munchen, Germany. | 8 years |
Julia Berretta | M | 43 |
GeneSpire Srl
![]() GeneSpire Srl BiotechnologyHealth Technology GeneSpire Srl is a holding company, which engages in the development of transformative gene therapies for patients with genetic diseases. The company was founded by Luigi Naldini and Alessio Cantone in March 2020 and is headquartered in Milan, Italy. | 4 years |
James B. Summers | M | - |
MISSION Therapeutics Ltd.
![]() MISSION Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology MISSION Therapeutics Ltd. develops small molecule drugs targeting enzymes involved in cancer and other diseases. It focuses on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases. The company was founded by Stephen Jackson Philip, Xavier Jacq, Niall M. B. Martin and Keith Menear in 2011 and is headquartered in Cambridge, the United Kingdom. | 5 years |
David Kaufman | M | 51 | 5 years | |
Pascal Haenggi | M | - |
Polyneuron Pharmaceuticals AG
![]() Polyneuron Pharmaceuticals AG Pharmaceuticals: MajorHealth Technology Polyneuron Pharmaceuticals AG develops drugs for the treatment of autoimmune disorders. It develops drugs for the treatment of anti-MAG neuropathy disease and multifocal motor neuropathy disease. The firm also develops antibody-catch, a platform technology that enables the development of drugs for highly specific interception of autoimmune disease antibodies and focuses on autoimmune diseases of the peripheral nervous system that involve autoantibodies against carbohydrate epitopes. The company was founded by Andreas J. Steck, Beat Ernst, Pascal Hänggi and Ruben Herrendorffin in 2014 and is headquartered in Basel, Switzerland. | 10 years |
Mano Iyer | M | - |
Sofinnova Partners SAS
![]() Sofinnova Partners SAS Investment ManagersFinance Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco. | 9 years |
Geraldine Harriman | - | - |
HotSpot Therapeutics, Inc.
![]() HotSpot Therapeutics, Inc. BiotechnologyHealth Technology HotSpot Therapeutics, Inc. develops new allosteric therapies with the ability to treat disease. The company was founded by Jonathan Montagu and Geraldine Harriman and is headquartered in Boston, MA. | - |
Klaus Orlinger | M | 46 | 12 years | |
Paul-Henri Lambert | M | 85 |
Hookipa Biotech AG
![]() Hookipa Biotech AG Medical SpecialtiesHealth Technology Hookipa Biotech AG develops new generation prophylactic and therapeutic vaccines. The firm’s Vaxwave technology is a novel immunotherapy platform using a replication-defective viral vector for the prevention and treatment of cancer and infectious diseases. The company was founded by Lukas Flatz, Andreas Bergthaler, Rolf M. Zinkernagel and Daniel Pinschewer in July 2011 and is headquartered in Vienna, Austria. | 9 years |
Madhav Devalaraja | M | 59 |
Corvidia Therapeutics, Inc.
![]() Corvidia Therapeutics, Inc. BiotechnologyHealth Technology Corvidia Therapeutics, Inc. is a biotechnology company focusing on cardiovascular therapies. It develops treatments for atherosclerotic cardiovascular disease, inflammation in chronic kidney diseases, and high triglyceride-induced acute pancreatitis. The company was founded by Michael H. Davidson, Rahul Kakkar, Matt Devalaraja, and Ram Aiyar in 2015 and is headquartered in Waltham, MA. | 9 years |
Stephen Philip Jackson | M | - |
MISSION Therapeutics Ltd.
![]() MISSION Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology MISSION Therapeutics Ltd. develops small molecule drugs targeting enzymes involved in cancer and other diseases. It focuses on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases. The company was founded by Stephen Jackson Philip, Xavier Jacq, Niall M. B. Martin and Keith Menear in 2011 and is headquartered in Cambridge, the United Kingdom. | 13 years |
Oliver Denk | M | - |
Breath Therapeutics GmbH
![]() Breath Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Breath Therapeutics GmbH is a clinical stage biopharmaceutical company, which engages in the development of inhaled therapeutics for respiratory diseases. It offers drug device platform, which consists of liposomal drug-aerosol formulations and cutting-edge inhalation technology. The company was founded by Jens Stegemann, Gerhard Boerner, Oliver Denk, and Anne Burger in 2016 and is headquartered in Munchen, Germany. | 8 years |
Igor Matushansky | M | 51 |
Crescendo Biologics Ltd.
![]() Crescendo Biologics Ltd. Miscellaneous Commercial ServicesCommercial Services Crescendo Biologics Ltd. engages in the development of new medicines based on antibody fragment technology. Its products in pipeline in dermatology include CB001, a transformational Humabody-based topical biologic for psoriasis which combines exceptional activity against a validated target with a topical route of delivery to avoid systemic side effects. The firm?s oncology products in pipeline include Humabody Multi-Specific T-Cell Engagers, Humabody Antibody Drug Conjugates and Immune Checkpoint Inhibitors. The company was founded by Michael Anthony Romanos, David Rayll Brown and John Bradshaw on November 13, 2007 and is headquartered in Cambridge, the United Kingdom. | 7 years |
Julie O'Neill | F | 58 | 6 years | |
Santiago Arroyo | M | 64 |
GlycoEra AG
![]() GlycoEra AG BiotechnologyHealth Technology GlycoEra AG is a Swiss biotechnology company specializing in the development of novel biologics for various indications. The company is based in Schlieren, Switzerland, and the USA. The company utilizes its innovative customglycan platform to design, engineer, and develop medicines based on deep expertise in glycobiology. GlycoEra has raised over $49 million in a 2021 series A financing round co-led by 5AM Ventures, Sofinnova Partners, and Roche Venture Fund. The company was founded by Dominique Sirena, Amir Faridmoayer, and Veronica Gambillara Fonck. Ganesh Venkataraman Kaundinya has been the CEO of the company since 2020. | 1 years |
Brian McGuinness | M | - |
Crescendo Biologics Ltd.
![]() Crescendo Biologics Ltd. Miscellaneous Commercial ServicesCommercial Services Crescendo Biologics Ltd. engages in the development of new medicines based on antibody fragment technology. Its products in pipeline in dermatology include CB001, a transformational Humabody-based topical biologic for psoriasis which combines exceptional activity against a validated target with a topical route of delivery to avoid systemic side effects. The firm?s oncology products in pipeline include Humabody Multi-Specific T-Cell Engagers, Humabody Antibody Drug Conjugates and Immune Checkpoint Inhibitors. The company was founded by Michael Anthony Romanos, David Rayll Brown and John Bradshaw on November 13, 2007 and is headquartered in Cambridge, the United Kingdom. | - |
Reinhard Kandera | M | 54 | 7 years | |
Theodora Caroline Harold | F | 50 |
Crescendo Biologics Ltd.
![]() Crescendo Biologics Ltd. Miscellaneous Commercial ServicesCommercial Services Crescendo Biologics Ltd. engages in the development of new medicines based on antibody fragment technology. Its products in pipeline in dermatology include CB001, a transformational Humabody-based topical biologic for psoriasis which combines exceptional activity against a validated target with a topical route of delivery to avoid systemic side effects. The firm?s oncology products in pipeline include Humabody Multi-Specific T-Cell Engagers, Humabody Antibody Drug Conjugates and Immune Checkpoint Inhibitors. The company was founded by Michael Anthony Romanos, David Rayll Brown and John Bradshaw on November 13, 2007 and is headquartered in Cambridge, the United Kingdom. | 8 years |
Warren Viricel | M | - |
Mablink Bioscience
![]() Mablink Bioscience Pharmaceuticals: MajorHealth Technology Mablink Bioscience is a biotechnology company based in Lyon, France that develops next-generation antibody-drug conjugates for the treatment of solid tumors. Mablink Bioscience's exclusive PSarlink™ platform is a unique stealth technology that "masks" the hydrophobicity of the cytotoxic drugs by adding a polysarcosine chain to the linker. The French company's pipeline is built on the topoisomerase-I inhibitor exatecan as a payload for current developments. Recently, the company announced the publication of a review article titled “Payload Diversification\: A Key Step in the Development of Antibody–Drug Conjugates” which reviews the history of the successes and failures in ADC payloads and takes a look at the new roads currently explored by the industry. The company was founded in 2018 by Warren Viricel and Jean-Guillaume Lafay, with Jean-Guillaume Lafay serving as CEO since then. | 6 years |
Anker Gunvald Lundemose | M | 63 |
MISSION Therapeutics Ltd.
![]() MISSION Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology MISSION Therapeutics Ltd. develops small molecule drugs targeting enzymes involved in cancer and other diseases. It focuses on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases. The company was founded by Stephen Jackson Philip, Xavier Jacq, Niall M. B. Martin and Keith Menear in 2011 and is headquartered in Cambridge, the United Kingdom. | - |
Colin Goddard | M | 64 |
MISSION Therapeutics Ltd.
![]() MISSION Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology MISSION Therapeutics Ltd. develops small molecule drugs targeting enzymes involved in cancer and other diseases. It focuses on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases. The company was founded by Stephen Jackson Philip, Xavier Jacq, Niall M. B. Martin and Keith Menear in 2011 and is headquartered in Cambridge, the United Kingdom. | 9 years |
Mats Eklund | M | - |
Sofinnova Partners SAS
![]() Sofinnova Partners SAS Investment ManagersFinance Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco. | 2 years |
Michael G. Moore | M | - |
MISSION Therapeutics Ltd.
![]() MISSION Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology MISSION Therapeutics Ltd. develops small molecule drugs targeting enzymes involved in cancer and other diseases. It focuses on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases. The company was founded by Stephen Jackson Philip, Xavier Jacq, Niall M. B. Martin and Keith Menear in 2011 and is headquartered in Cambridge, the United Kingdom. | 12 years |
Gerraldine Harriman | M | - |
HotSpot Therapeutics, Inc.
![]() HotSpot Therapeutics, Inc. BiotechnologyHealth Technology HotSpot Therapeutics, Inc. develops new allosteric therapies with the ability to treat disease. The company was founded by Jonathan Montagu and Geraldine Harriman and is headquartered in Boston, MA. | 7 years |
Monique Saulnier | F | - |
Sofinnova Partners SAS
![]() Sofinnova Partners SAS Investment ManagersFinance Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco. | 41 years |
Denis Lucquin | M | 67 |
Sofinnova Partners SAS
![]() Sofinnova Partners SAS Investment ManagersFinance Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco. | 33 years |
Lucia Faccio | M | - |
GeneSpire Srl
![]() GeneSpire Srl BiotechnologyHealth Technology GeneSpire Srl is a holding company, which engages in the development of transformative gene therapies for patients with genetic diseases. The company was founded by Luigi Naldini and Alessio Cantone in March 2020 and is headquartered in Milan, Italy.
Sofinnova Partners SAS
![]() Sofinnova Partners SAS Investment ManagersFinance Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco. | 6 years |
David Sourdive | M | 57 |
Mablink Bioscience
![]() Mablink Bioscience Pharmaceuticals: MajorHealth Technology Mablink Bioscience is a biotechnology company based in Lyon, France that develops next-generation antibody-drug conjugates for the treatment of solid tumors. Mablink Bioscience's exclusive PSarlink™ platform is a unique stealth technology that "masks" the hydrophobicity of the cytotoxic drugs by adding a polysarcosine chain to the linker. The French company's pipeline is built on the topoisomerase-I inhibitor exatecan as a payload for current developments. Recently, the company announced the publication of a review article titled “Payload Diversification\: A Key Step in the Development of Antibody–Drug Conjugates” which reviews the history of the successes and failures in ADC payloads and takes a look at the new roads currently explored by the industry. The company was founded in 2018 by Warren Viricel and Jean-Guillaume Lafay, with Jean-Guillaume Lafay serving as CEO since then. | 3 years |
Anne Burger | F | - |
Breath Therapeutics GmbH
![]() Breath Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Breath Therapeutics GmbH is a clinical stage biopharmaceutical company, which engages in the development of inhaled therapeutics for respiratory diseases. It offers drug device platform, which consists of liposomal drug-aerosol formulations and cutting-edge inhalation technology. The company was founded by Jens Stegemann, Gerhard Boerner, Oliver Denk, and Anne Burger in 2016 and is headquartered in Munchen, Germany. | 8 years |
Eddy Anglade | M | 62 |
Tenpoint Therapeutics Ltd.
![]() Tenpoint Therapeutics Ltd. BiotechnologyHealth Technology Tenpoint Therapeutics Ltd. is a British biotechnology company that specializes in developing engineered cell-based therapies and in vivo reprogramming to restore vision for individuals with degenerative ocular diseases. The company is based in Cambridge, UK and was founded in 2020. Tenpoint Therapeutics brings together experts who are shaping the regenerative ocular medicine revolution and the technologies that are driving it. The company's focus is on replacing diseased cells with healthy ones to permanently restore vision. Eddy Anglade has been the CEO of the company since 2023. | 1 years |
Cécile Dupont Redon | F | - |
Sofinnova Partners SAS
![]() Sofinnova Partners SAS Investment ManagersFinance Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco. | 5 years |
Anta Gkelou | M | 38 |
Sofinnova Partners SAS
![]() Sofinnova Partners SAS Investment ManagersFinance Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco. | 7 years |
Zhizhong Yao | M | - |
Sofinnova Partners SAS
![]() Sofinnova Partners SAS Investment ManagersFinance Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco. | 9 years |
Roman Necina | M | 56 | 5 years | |
Guillaume Baxter | M | - |
Sofinnova Partners SAS
![]() Sofinnova Partners SAS Investment ManagersFinance Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco. | 7 years |
Gerhard Boerner | M | - |
Breath Therapeutics GmbH
![]() Breath Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Breath Therapeutics GmbH is a clinical stage biopharmaceutical company, which engages in the development of inhaled therapeutics for respiratory diseases. It offers drug device platform, which consists of liposomal drug-aerosol formulations and cutting-edge inhalation technology. The company was founded by Jens Stegemann, Gerhard Boerner, Oliver Denk, and Anne Burger in 2016 and is headquartered in Munchen, Germany. | 8 years |
Ming Cheah | M | - |
HotSpot Therapeutics, Inc.
![]() HotSpot Therapeutics, Inc. BiotechnologyHealth Technology HotSpot Therapeutics, Inc. develops new allosteric therapies with the ability to treat disease. The company was founded by Jonathan Montagu and Geraldine Harriman and is headquartered in Boston, MA. | 3 years |
Timothy Reilly | M | 50 |
HotSpot Therapeutics, Inc.
![]() HotSpot Therapeutics, Inc. BiotechnologyHealth Technology HotSpot Therapeutics, Inc. develops new allosteric therapies with the ability to treat disease. The company was founded by Jonathan Montagu and Geraldine Harriman and is headquartered in Boston, MA. | - |
Denis Patrick | M | - |
MISSION Therapeutics Ltd.
![]() MISSION Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology MISSION Therapeutics Ltd. develops small molecule drugs targeting enzymes involved in cancer and other diseases. It focuses on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases. The company was founded by Stephen Jackson Philip, Xavier Jacq, Niall M. B. Martin and Keith Menear in 2011 and is headquartered in Cambridge, the United Kingdom. | - |
Franz Heinz | M | - |
Hookipa Biotech AG
![]() Hookipa Biotech AG Medical SpecialtiesHealth Technology Hookipa Biotech AG develops new generation prophylactic and therapeutic vaccines. The firm’s Vaxwave technology is a novel immunotherapy platform using a replication-defective viral vector for the prevention and treatment of cancer and infectious diseases. The company was founded by Lukas Flatz, Andreas Bergthaler, Rolf M. Zinkernagel and Daniel Pinschewer in July 2011 and is headquartered in Vienna, Austria. | - |
Amit K Shah | M | - |
HotSpot Therapeutics, Inc.
![]() HotSpot Therapeutics, Inc. BiotechnologyHealth Technology HotSpot Therapeutics, Inc. develops new allosteric therapies with the ability to treat disease. The company was founded by Jonathan Montagu and Geraldine Harriman and is headquartered in Boston, MA. | - |
Vera Strasser | F | - |
Hookipa Biotech AG
![]() Hookipa Biotech AG Medical SpecialtiesHealth Technology Hookipa Biotech AG develops new generation prophylactic and therapeutic vaccines. The firm’s Vaxwave technology is a novel immunotherapy platform using a replication-defective viral vector for the prevention and treatment of cancer and infectious diseases. The company was founded by Lukas Flatz, Andreas Bergthaler, Rolf M. Zinkernagel and Daniel Pinschewer in July 2011 and is headquartered in Vienna, Austria. | - |
Lukas Flatz | M | - |
Hookipa Biotech AG
![]() Hookipa Biotech AG Medical SpecialtiesHealth Technology Hookipa Biotech AG develops new generation prophylactic and therapeutic vaccines. The firm’s Vaxwave technology is a novel immunotherapy platform using a replication-defective viral vector for the prevention and treatment of cancer and infectious diseases. The company was founded by Lukas Flatz, Andreas Bergthaler, Rolf M. Zinkernagel and Daniel Pinschewer in July 2011 and is headquartered in Vienna, Austria. | 13 years |
Arnaud Marchant | M | - |
Hookipa Biotech AG
![]() Hookipa Biotech AG Medical SpecialtiesHealth Technology Hookipa Biotech AG develops new generation prophylactic and therapeutic vaccines. The firm’s Vaxwave technology is a novel immunotherapy platform using a replication-defective viral vector for the prevention and treatment of cancer and infectious diseases. The company was founded by Lukas Flatz, Andreas Bergthaler, Rolf M. Zinkernagel and Daniel Pinschewer in July 2011 and is headquartered in Vienna, Austria. | - |
Mira Chaurushiya | M | - |
GlycoEra AG
![]() GlycoEra AG BiotechnologyHealth Technology GlycoEra AG is a Swiss biotechnology company specializing in the development of novel biologics for various indications. The company is based in Schlieren, Switzerland, and the USA. The company utilizes its innovative customglycan platform to design, engineer, and develop medicines based on deep expertise in glycobiology. GlycoEra has raised over $49 million in a 2021 series A financing round co-led by 5AM Ventures, Sofinnova Partners, and Roche Venture Fund. The company was founded by Dominique Sirena, Amir Faridmoayer, and Veronica Gambillara Fonck. Ganesh Venkataraman Kaundinya has been the CEO of the company since 2020. | - |
Anna Louise French | F | 37 |
Tenpoint Therapeutics Ltd.
![]() Tenpoint Therapeutics Ltd. BiotechnologyHealth Technology Tenpoint Therapeutics Ltd. is a British biotechnology company that specializes in developing engineered cell-based therapies and in vivo reprogramming to restore vision for individuals with degenerative ocular diseases. The company is based in Cambridge, UK and was founded in 2020. Tenpoint Therapeutics brings together experts who are shaping the regenerative ocular medicine revolution and the technologies that are driving it. The company's focus is on replacing diseased cells with healthy ones to permanently restore vision. Eddy Anglade has been the CEO of the company since 2023. | - |
Luke Beshar | M | 65 |
Inotrem SA
![]() Inotrem SA BiotechnologyHealth Technology Inotrem SA specializes in the development of therapeutic approaches based on its proprietary TREM-1 platform. The firm focuses on the control of immune reactions in acute inflammatory diseases. The company was founded by Jean-Jacques Garaud, Marc Derive and Sebastien Gibot in 2013 and is headquartered in Paris, France. | 3 years |
David Luther | M | - |
MISSION Therapeutics Ltd.
![]() MISSION Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology MISSION Therapeutics Ltd. develops small molecule drugs targeting enzymes involved in cancer and other diseases. It focuses on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases. The company was founded by Stephen Jackson Philip, Xavier Jacq, Niall M. B. Martin and Keith Menear in 2011 and is headquartered in Cambridge, the United Kingdom. | 9 years |
Claudio Giuliano | M | 53 |
EryDel SpA
![]() EryDel SpA Medical SpecialtiesHealth Technology EryDel SpA offers medical research. It develops drugs and diagnostics delivered through human red blood cells via a medical device technology. The company was founded by Luigia Rossi and Mauro Magnani in 2007 and is headquartered in Bresso, Italy. | - |
Carole Nüchterlein | F | 62 |
MISSION Therapeutics Ltd.
![]() MISSION Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology MISSION Therapeutics Ltd. develops small molecule drugs targeting enzymes involved in cancer and other diseases. It focuses on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases. The company was founded by Stephen Jackson Philip, Xavier Jacq, Niall M. B. Martin and Keith Menear in 2011 and is headquartered in Cambridge, the United Kingdom. | 7 years |
Sylvie Grégoire | M | 62 |
Corvidia Therapeutics, Inc.
![]() Corvidia Therapeutics, Inc. BiotechnologyHealth Technology Corvidia Therapeutics, Inc. is a biotechnology company focusing on cardiovascular therapies. It develops treatments for atherosclerotic cardiovascular disease, inflammation in chronic kidney diseases, and high triglyceride-induced acute pancreatitis. The company was founded by Michael H. Davidson, Rahul Kakkar, Matt Devalaraja, and Ram Aiyar in 2015 and is headquartered in Waltham, MA. | 8 years |
Dan Omstead | M | 71 |
HotSpot Therapeutics, Inc.
![]() HotSpot Therapeutics, Inc. BiotechnologyHealth Technology HotSpot Therapeutics, Inc. develops new allosteric therapies with the ability to treat disease. The company was founded by Jonathan Montagu and Geraldine Harriman and is headquartered in Boston, MA. | 3 years |
Maria Gabriella Camboni | M | 66 |
MISSION Therapeutics Ltd.
![]() MISSION Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology MISSION Therapeutics Ltd. develops small molecule drugs targeting enzymes involved in cancer and other diseases. It focuses on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases. The company was founded by Stephen Jackson Philip, Xavier Jacq, Niall M. B. Martin and Keith Menear in 2011 and is headquartered in Cambridge, the United Kingdom. | - |
Jean-Marie Paluel-Marmont | M | 81 |
Sofinnova Partners SAS
![]() Sofinnova Partners SAS Investment ManagersFinance Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco. | - |
Gérard Hascoët | M | 75 |
Sofinnova Partners SAS
![]() Sofinnova Partners SAS Investment ManagersFinance Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco. | 20 years |
Elaine Jones | M | 69 |
MISSION Therapeutics Ltd.
![]() MISSION Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology MISSION Therapeutics Ltd. develops small molecule drugs targeting enzymes involved in cancer and other diseases. It focuses on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases. The company was founded by Stephen Jackson Philip, Xavier Jacq, Niall M. B. Martin and Keith Menear in 2011 and is headquartered in Cambridge, the United Kingdom. | - |
Fouad Azzam | M | 57 |
HotSpot Therapeutics, Inc.
![]() HotSpot Therapeutics, Inc. BiotechnologyHealth Technology HotSpot Therapeutics, Inc. develops new allosteric therapies with the ability to treat disease. The company was founded by Jonathan Montagu and Geraldine Harriman and is headquartered in Boston, MA. | - |
Alexander G. Asam | M | 58 |
Corvidia Therapeutics, Inc.
![]() Corvidia Therapeutics, Inc. BiotechnologyHealth Technology Corvidia Therapeutics, Inc. is a biotechnology company focusing on cardiovascular therapies. It develops treatments for atherosclerotic cardiovascular disease, inflammation in chronic kidney diseases, and high triglyceride-induced acute pancreatitis. The company was founded by Michael H. Davidson, Rahul Kakkar, Matt Devalaraja, and Ram Aiyar in 2015 and is headquartered in Waltham, MA. | - |
Thomas Möller | M | 54 |
Inotrem SA
![]() Inotrem SA BiotechnologyHealth Technology Inotrem SA specializes in the development of therapeutic approaches based on its proprietary TREM-1 platform. The firm focuses on the control of immune reactions in acute inflammatory diseases. The company was founded by Jean-Jacques Garaud, Marc Derive and Sebastien Gibot in 2013 and is headquartered in Paris, France. | - |
François Thomas | M | 66 |
Inotrem SA
![]() Inotrem SA BiotechnologyHealth Technology Inotrem SA specializes in the development of therapeutic approaches based on its proprietary TREM-1 platform. The firm focuses on the control of immune reactions in acute inflammatory diseases. The company was founded by Jean-Jacques Garaud, Marc Derive and Sebastien Gibot in 2013 and is headquartered in Paris, France. | - |
Bruce Booth | M | 49 |
HotSpot Therapeutics, Inc.
![]() HotSpot Therapeutics, Inc. BiotechnologyHealth Technology HotSpot Therapeutics, Inc. develops new allosteric therapies with the ability to treat disease. The company was founded by Jonathan Montagu and Geraldine Harriman and is headquartered in Boston, MA. | 7 years |
Deborah Harland | M | 64 |
MISSION Therapeutics Ltd.
![]() MISSION Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology MISSION Therapeutics Ltd. develops small molecule drugs targeting enzymes involved in cancer and other diseases. It focuses on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases. The company was founded by Stephen Jackson Philip, Xavier Jacq, Niall M. B. Martin and Keith Menear in 2011 and is headquartered in Cambridge, the United Kingdom. | - |
Jose Carmona | M | 51 |
HotSpot Therapeutics, Inc.
![]() HotSpot Therapeutics, Inc. BiotechnologyHealth Technology HotSpot Therapeutics, Inc. develops new allosteric therapies with the ability to treat disease. The company was founded by Jonathan Montagu and Geraldine Harriman and is headquartered in Boston, MA. | - |
Paolo Fundarò | M | 50 |
EryDel SpA
![]() EryDel SpA Medical SpecialtiesHealth Technology EryDel SpA offers medical research. It develops drugs and diagnostics delivered through human red blood cells via a medical device technology. The company was founded by Luigia Rossi and Mauro Magnani in 2007 and is headquartered in Bresso, Italy. | 11 years |
Jonathan Hepple | M | 53 |
MISSION Therapeutics Ltd.
![]() MISSION Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology MISSION Therapeutics Ltd. develops small molecule drugs targeting enzymes involved in cancer and other diseases. It focuses on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases. The company was founded by Stephen Jackson Philip, Xavier Jacq, Niall M. B. Martin and Keith Menear in 2011 and is headquartered in Cambridge, the United Kingdom. | 3 years |
Ena Prossner | M | 58 |
Inotrem SA
![]() Inotrem SA BiotechnologyHealth Technology Inotrem SA specializes in the development of therapeutic approaches based on its proprietary TREM-1 platform. The firm focuses on the control of immune reactions in acute inflammatory diseases. The company was founded by Jean-Jacques Garaud, Marc Derive and Sebastien Gibot in 2013 and is headquartered in Paris, France. | 4 years |
Victoria Richon | M | 65 |
HotSpot Therapeutics, Inc.
![]() HotSpot Therapeutics, Inc. BiotechnologyHealth Technology HotSpot Therapeutics, Inc. develops new allosteric therapies with the ability to treat disease. The company was founded by Jonathan Montagu and Geraldine Harriman and is headquartered in Boston, MA. | 6 years |
Thomas Hughes | M | 64 |
HotSpot Therapeutics, Inc.
![]() HotSpot Therapeutics, Inc. BiotechnologyHealth Technology HotSpot Therapeutics, Inc. develops new allosteric therapies with the ability to treat disease. The company was founded by Jonathan Montagu and Geraldine Harriman and is headquartered in Boston, MA. | - |
Monique Schiersing | M | - |
GlycoEra AG
![]() GlycoEra AG BiotechnologyHealth Technology GlycoEra AG is a Swiss biotechnology company specializing in the development of novel biologics for various indications. The company is based in Schlieren, Switzerland, and the USA. The company utilizes its innovative customglycan platform to design, engineer, and develop medicines based on deep expertise in glycobiology. GlycoEra has raised over $49 million in a 2021 series A financing round co-led by 5AM Ventures, Sofinnova Partners, and Roche Venture Fund. The company was founded by Dominique Sirena, Amir Faridmoayer, and Veronica Gambillara Fonck. Ganesh Venkataraman Kaundinya has been the CEO of the company since 2020. | - |
Bobby G. Soni | M | 53 |
MISSION Therapeutics Ltd.
![]() MISSION Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology MISSION Therapeutics Ltd. develops small molecule drugs targeting enzymes involved in cancer and other diseases. It focuses on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases. The company was founded by Stephen Jackson Philip, Xavier Jacq, Niall M. B. Martin and Keith Menear in 2011 and is headquartered in Cambridge, the United Kingdom. | - |
Jill Carroll | F | 48 |
HotSpot Therapeutics, Inc.
![]() HotSpot Therapeutics, Inc. BiotechnologyHealth Technology HotSpot Therapeutics, Inc. develops new allosteric therapies with the ability to treat disease. The company was founded by Jonathan Montagu and Geraldine Harriman and is headquartered in Boston, MA. | - |
Frank Kalkbrenner | M | - |
Hookipa Biotech AG
![]() Hookipa Biotech AG Medical SpecialtiesHealth Technology Hookipa Biotech AG develops new generation prophylactic and therapeutic vaccines. The firm’s Vaxwave technology is a novel immunotherapy platform using a replication-defective viral vector for the prevention and treatment of cancer and infectious diseases. The company was founded by Lukas Flatz, Andreas Bergthaler, Rolf M. Zinkernagel and Daniel Pinschewer in July 2011 and is headquartered in Vienna, Austria. | 11 years |
Georges Gemayel | M | 63 |
GlycoEra AG
![]() GlycoEra AG BiotechnologyHealth Technology GlycoEra AG is a Swiss biotechnology company specializing in the development of novel biologics for various indications. The company is based in Schlieren, Switzerland, and the USA. The company utilizes its innovative customglycan platform to design, engineer, and develop medicines based on deep expertise in glycobiology. GlycoEra has raised over $49 million in a 2021 series A financing round co-led by 5AM Ventures, Sofinnova Partners, and Roche Venture Fund. The company was founded by Dominique Sirena, Amir Faridmoayer, and Veronica Gambillara Fonck. Ganesh Venkataraman Kaundinya has been the CEO of the company since 2020. | 2 years |
Matthew McAviney | M | - |
Polyneuron Pharmaceuticals AG
![]() Polyneuron Pharmaceuticals AG Pharmaceuticals: MajorHealth Technology Polyneuron Pharmaceuticals AG develops drugs for the treatment of autoimmune disorders. It develops drugs for the treatment of anti-MAG neuropathy disease and multifocal motor neuropathy disease. The firm also develops antibody-catch, a platform technology that enables the development of drugs for highly specific interception of autoimmune disease antibodies and focuses on autoimmune diseases of the peripheral nervous system that involve autoantibodies against carbohydrate epitopes. The company was founded by Andreas J. Steck, Beat Ernst, Pascal Hänggi and Ruben Herrendorffin in 2014 and is headquartered in Basel, Switzerland. | - |
Armance Bordes | F | 45 |
Sofinnova Partners SAS
![]() Sofinnova Partners SAS Investment ManagersFinance Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco. | - |
Paul Eisenberg | M | - |
Corvidia Therapeutics, Inc.
![]() Corvidia Therapeutics, Inc. BiotechnologyHealth Technology Corvidia Therapeutics, Inc. is a biotechnology company focusing on cardiovascular therapies. It develops treatments for atherosclerotic cardiovascular disease, inflammation in chronic kidney diseases, and high triglyceride-induced acute pancreatitis. The company was founded by Michael H. Davidson, Rahul Kakkar, Matt Devalaraja, and Ram Aiyar in 2015 and is headquartered in Waltham, MA. | - |
Shinichiro Komoto | M | 47 |
Tenpoint Therapeutics Ltd.
![]() Tenpoint Therapeutics Ltd. BiotechnologyHealth Technology Tenpoint Therapeutics Ltd. is a British biotechnology company that specializes in developing engineered cell-based therapies and in vivo reprogramming to restore vision for individuals with degenerative ocular diseases. The company is based in Cambridge, UK and was founded in 2020. Tenpoint Therapeutics brings together experts who are shaping the regenerative ocular medicine revolution and the technologies that are driving it. The company's focus is on replacing diseased cells with healthy ones to permanently restore vision. Eddy Anglade has been the CEO of the company since 2023. | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Jean-Bernard Schmidt | M | 78 |
Sofinnova Partners SAS
![]() Sofinnova Partners SAS Investment ManagersFinance Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco. | 37 years |
Olivier Protard | M | - |
Sofinnova Partners SAS
![]() Sofinnova Partners SAS Investment ManagersFinance Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco. | 18 years |
Alessio Beverina | M | - |
Sofinnova Partners SAS
![]() Sofinnova Partners SAS Investment ManagersFinance Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco. | 10 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 29 | 29.00% |
France | 29 | 29.00% |
United Kingdom | 21 | 21.00% |
Switzerland | 12 | 12.00% |
Austria | 11 | 11.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Graziano Seghezzi
- Personal Network